Gene expression changes in the medial prefrontal cortex and nucleus accumbens following abstinence from cocaine self-administration.

Publisher: BioMed Central Country of Publication: England NLM ID: 100966986 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2202 (Electronic) Linking ISSN: 14712202 NLM ISO Abbreviation: BMC Neurosci Subsets: MEDLINE

Original Publication: London: BioMed Central, [2000-

Gene Expression*; Cocaine/*administration & dosage ; Cocaine-Related Disorders/*genetics ; Dopamine Uptake Inhibitors/*administration & dosage ; Nucleus Accumbens/*metabolism ; Prefrontal Cortex/*metabolism ; Substance Withdrawal Syndrome/*genetics; Analysis of Variance ; Animals ; Cocaine/pharmacology ; Cocaine-Related Disorders/metabolism ; Disease Models, Animal ; Dopamine Uptake Inhibitors/pharmacology ; Male ; Nucleus Accumbens/drug effects ; Oligonucleotide Array Sequence Analysis ; Polymerase Chain Reaction ; Prefrontal Cortex/drug effects ; Rats ; Rats, Sprague-Dawley ; Self Administration ; Substance Withdrawal Syndrome/metabolism ; Time Factors

Background: Many studies of cocaine-responsive gene expression have focused on changes occurring during cocaine exposure, but few studies have examined the persistence of these changes with cocaine abstinence. Persistent changes in gene expression, as well as alterations induced during abstinence may underlie long-lasting drug craving and relapse liability.
Results: Whole-genome expression analysis was conducted on a rat cocaine binge-abstinence model that has previously been demonstrated to engender increased drug seeking and taking with abstinence. Gene expression changes in two mesolimbic terminal fields (mPFC and NAc) were identified in a comparison of cocaine-naïve rats with rats after 10 days of cocaine self-administration followed by 1, 10, or 100 days of enforced abstinence (n = 6-11 per group). A total of 1,461 genes in the mPFC and 414 genes in the NAc were altered between at least two time points (ANOVA, p < 0.05; +/- 1.4 fold-change). These genes can be subdivided into: 1) changes with cocaine self-administration that do not persist into periods of abstinence, 2) changes with cocaine self-administration that persist with abstinence, 3) and those not changed with cocaine self-administration, but changed during enforced abstinence. qPCR analysis was conducted to confirm gene expression changes observed in the microarray analysis.
Conclusions: Together, these changes help to illuminate processes and networks involved in abstinence-induced behaviors, including synaptic plasticity, MAPK signaling, and TNF signaling.

Alcohol Clin Exp Res. 1993 Jun;17(3):580-5. (PMID: 8101433)
Arch Gen Psychiatry. 1986 Feb;43(2):107-13. (PMID: 3947206)
Ann N Y Acad Sci. 2008 Oct;1141:58-75. (PMID: 18991951)
J Neurosci. 1998 Jun 1;18(11):4305-13. (PMID: 9592107)
Drug Alcohol Depend. 2006 Feb 28;81(3):267-74. (PMID: 16169160)
Nat Rev Genet. 2006 Jan;7(1):55-65. (PMID: 16369572)
Behav Cogn Neurosci Rev. 2002 Dec;1(4):281-96. (PMID: 17712985)
Hum Genet. 2007 Apr;121(2):243-56. (PMID: 17203304)
J Consult Clin Psychol. 1996 Aug;64(4):677-86. (PMID: 8803357)
Life Sci. 2007 Jan 23;80(7):690-8. (PMID: 17157329)
Addiction. 2003 Mar;98(3):291-303. (PMID: 12603229)
Hippocampus. 2008;18(6):564-74. (PMID: 18306304)
Biotechniques. 1995 Dec;19(6):942-5. (PMID: 8747660)
J Subst Abuse Treat. 1989;6(2):95-106. (PMID: 2746717)
Trends Neurosci. 2006 Dec;29(12):695-703. (PMID: 17084911)
Biol Psychiatry. 2008 Feb 1;63(3):256-62. (PMID: 17719014)
Neurosci Biobehav Rev. 2004 Jan;27(8):803-12. (PMID: 15019429)
J Neurosci Res. 2009 Feb;87(2):380-92. (PMID: 18798281)
Eur J Neurosci. 2003 Mar;17(6):1273-8. (PMID: 12670315)
Int J Immunopharmacol. 1994 Apr;16(4):295-300. (PMID: 8045669)
Mol Biol Cell. 2004 May;15(5):2324-34. (PMID: 15004221)
J Neurophysiol. 2001 Jan;85(1):117-24. (PMID: 11152712)
J Neurosci. 2004 Jan 7;24(1):8-23. (PMID: 14715933)
Prog Brain Res. 2006;158:173-95. (PMID: 17027697)
Eur J Neurosci. 2002 Sep;16(5):877-82. (PMID: 12372024)
Neuroscience. 2007 Jan 5;144(1):66-76. (PMID: 17049170)
Neuron. 2006 Nov 9;52(3):437-44. (PMID: 17088210)
Neuron. 2005 Oct 20;48(2):303-14. (PMID: 16242410)
Eur J Pharmacol. 2009 Mar 1;605(1-3):117-22. (PMID: 19171134)
Curr Opin Pharmacol. 2007 Feb;7(1):77-85. (PMID: 17085074)
Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8. (PMID: 2899326)
Psychopharmacology (Berl). 2003 Sep;169(2):161-8. (PMID: 12768268)
J Neurosci. 2006 Nov 29;26(48):12397-407. (PMID: 17135401)
Science. 2005 Nov 25;310(5752):1340-3. (PMID: 16311338)
J Biol Chem. 2006 Apr 28;281(17):11910-6. (PMID: 16501258)
Br J Pharmacol. 1997 Nov;122(6):1075-82. (PMID: 9401772)
Neuroscience. 2001;108(3):371-80. (PMID: 11738252)
Neurosci Lett. 2006 May 8;398(3):235-40. (PMID: 16459018)
J Neurochem. 2005 Feb;92(4):878-85. (PMID: 15686490)
J Pharmacol Sci. 2007 Jun;104(2):116-21. (PMID: 17538232)
Nature. 2001 Jul 12;412(6843):141-2. (PMID: 11449260)
Drug Alcohol Depend. 2010 Feb 1;107(1):11-22. (PMID: 19926406)
Neuron. 2006 Nov 9;52(3):403-7. (PMID: 17088207)
Trends Pharmacol Sci. 2004 Apr;25(4):210-8. (PMID: 15063085)
Synapse. 2000 Feb;35(2):137-43. (PMID: 10611639)
Nat Neurosci. 2009 Feb;12(2):182-9. (PMID: 19136971)
Psychopharmacology (Berl). 2005 Mar;178(2-3):309-16. (PMID: 15322729)
Neuropharmacology. 2004;47 Suppl 1:214-26. (PMID: 15464139)
Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12852-7. (PMID: 11058155)
Prog Neurobiol. 2004 Nov;74(4):183-211. (PMID: 15556287)
Life Sci. 2004 Oct 22;75(23):2751-64. (PMID: 15464827)
BMC Bioinformatics. 2004 Sep 06;5:124. (PMID: 15350198)
J Neurosci. 1992 Jun;12(6):2165-76. (PMID: 1376774)
Neurosci Biobehav Rev. 2002 Oct;26(6):631-64. (PMID: 12479840)
Psychopharmacology (Berl). 2001 Dec;158(4):343-59. (PMID: 11797055)
Nature. 2003 Jan 2;421(6918):70-5. (PMID: 12511956)
J Neurosci. 2001 Oct 1;21(19):7474-80. (PMID: 11567037)
Nature. 2008 Jul 3;454(7200):118-21. (PMID: 18500330)
Genomics. 1996 Jan 15;31(2):167-76. (PMID: 8824798)
Life Sci. 1994;54(6):401-11. (PMID: 8295487)
J Neurosci. 1998 Feb 15;18(4):1270-9. (PMID: 9454837)
Neuropsychopharmacology. 2005 Jan;30(1):205-11. (PMID: 15525998)
Neuron. 2002 Jul 3;35(1):91-105. (PMID: 12123611)
Brain Res. 1998 Jul 6;798(1-2):294-303. (PMID: 9666151)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Pharmacogenomics. 2008 Oct;9(10):1437-43. (PMID: 18855532)
Proteomics Clin Appl. 2009 Mar 17;3(4):462-472. (PMID: 20161123)
J Neurochem. 2003 Jun;85(6):1604-13. (PMID: 12787079)
J Neurochem. 2001 Apr;77(2):542-9. (PMID: 11299316)
Am J Psychiatry. 1999 Jan;156(1):11-8. (PMID: 9892292)
Behav Pharmacol. 2002 Sep;13(5-6):389-96. (PMID: 12394415)
J Neurosci. 2000 Jun 1;20(11):3993-4001. (PMID: 10818134)
Neuropsychopharmacology. 2008 Jul;33(8):1807-17. (PMID: 17851536)
BMC Med Genomics. 2008 Jun 13;1:26. (PMID: 18554398)
J Neurosci. 2005 Apr 13;25(15):3932-9. (PMID: 15829645)
J Consult Clin Psychol. 2000 Jun;68(3):515-20. (PMID: 10883569)
J Biol Chem. 2004 Oct 8;279(41):43245-53. (PMID: 15297459)
J Psychopharmacol. 1998;12(1):15-22. (PMID: 9584964)
Brain Res. 2008 Jun 5;1213:166-77. (PMID: 18452895)
Hippocampus. 2000;10(1):57-63. (PMID: 10706217)
Psychopharmacology (Berl). 2008 May;198(1):77-91. (PMID: 18311559)
Neuroscience. 2002;110(1):1-6. (PMID: 11882367)
Neuroimage. 2005 Jul 15;26(4):1097-108. (PMID: 15886020)

K01-DA13957 United States DA NIDA NIH HHS; R01-DA013770-08 United States DA NIDA NIH HHS; F31-DA02281902 United States DA NIDA NIH HHS; R01 DA14030 United States DA NIDA NIH HHS; R01 DA014030 United States DA NIDA NIH HHS

0 (Dopamine Uptake Inhibitors)
I5Y540LHVR (Cocaine)

Date Created: 20100302 Date Completed: 20100506 Latest Revision: 20211020

20240829

PMC2837051

10.1186/1471-2202-11-29

20187946